What do systematic reviews say?

Intervention not reported

• Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 267 participants
  Low

Animal‐assisted therapy (AAT (live animal)) vs robotic animals

• Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 78 participants
  Low

Animal‐assisted therapy (AAT (live animal)) vs no AAT

• Animal‐assisted therapy for dementia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Moderate

Whole‐facility changes: Home‐like models vs traditional environment

• Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
  no estimate extracted
  33 participants
  Very low

Next‐generation ALK inhibitor vs crizotinib

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 1.1 [0.72, 1.68]
  1 study · 303 participants
  Very low

ALK inhibitor vs any cytotoxic chemotherapy

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.52 [0.44, 0.6]
  5 studies · 1504 participants
  High

Mepolizumab 100 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1285 participants
  Moderate

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Surgical vs conservative interventions

• Surgical versus conservative interventions for treating fractures of the middle third of the clavicle 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 321 participants
  Low

Non‐invasive ventilation during exercise training vs exercise training alone or exercise training with sham non‐invasive ventilation

• Non‐invasive ventilation during exercise training for people with chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 48 participants
  Moderate

Mepolizumab 300 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 451 participants
  Moderate

Mepolizumab 100 mg vs placebo

• Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 911 participants
  Moderate

Mucolytic vs placebo

• Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2721 participants
  Moderate

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Neurodynamic mobilisation vs no treatment

It is very uncertain whether neurodynamic mobilisation changes short‐term improvement in functional ability or health‐related… compared with no treatment (very low certainty).

• Exercise and mobilisation interventions for carpal tunnel syndrome 2012 · Cochrane Headline outcomes only
  RR 9 [0.59, 137.65]
  1 study · 12 participants
  Very low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 8.82 [4.4, 17.69]
  1 study · 309 participants
  Low

Cognitive‐behavioural intervention vs controls

• Cognitive behavioural therapies for fibromyalgia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 1238 participants
  Low

Low‐dose computed tomography (LDCT) screening vs no LDCT screening

Low‐dose computed tomography (LDCT) screening showed no clear difference in health‐related quality of life ‐ anxiety Time point: 10 months to 5… compared with no LDCT screening (low certainty).

• Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 8153 participants
  Low